Drug

Interferon alfa-2b

Established medicine

ClassInterferon alpha/beta receptor agonistResearchOngoing clinical research

Also known as IFN alpha-2B, Interferon Alfa-2b (E. coli), Intron A, interferon alfa-2b,recomb.+9 more

IFN alpha-2B, Interferon Alfa-2b (E. coli), Intron A, interferon alfa-2b,recomb., r-INF-alpha, rIFN-alpha-2b, INTERFERON ALFA 2-B, Interferon alfa 2b, Interferon alpha-2B, INTERFERON ALFA-2B,RECOMBINANT, Interferon alfa-2b (recombinant), Interferon alfa-2b, recombinant, Recombinant Interferon Alfa-2b.

RxNorm5880 ChEMBLCHEMBL1201558 ATCL03AB05UNII43K1W2T1M6

Active clinical trials

Protein targets

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High Dose Interferon a-2b for Resected High Risk Melanoma

Clinical trial2026-08-04Results posted · ClinicalTrials.gov

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma

Clinical trial2026-07-02Results posted · ClinicalTrials.gov

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Clinical trial2026-06-25Results posted · ClinicalTrials.gov

Randomized Phase 2 Study: Neoadjuvant Conditioning of Prostate Cancer Tumor Microenvironment Using a Novel Chemokine-Modulating Regimen

Clinical trial2026-06-09Results expected Q2 2027 · ClinicalTrials.gov

A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma

Clinical trial2026-05-29Results posted · ClinicalTrials.gov

Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients

Clinical trial2026-05-29Results posted · ClinicalTrials.gov

Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma

Clinical trial2026-02-25Results posted · ClinicalTrials.gov

A Study to Explore the Efficacy and Safety of Interferon-α Combined With ATO and Venetoclax in the Treatment of Arsenic-resistant Acute Promyelocytic Leukemia

Clinical trial2025-12-31Primary completion · ClinicalTrials.gov

A Phase II Study of Type-1 Polarized Dendritic Cell (aDC1) -Based Treatment in Combination With Tumor-Selective Chemokine Modulation (CKM: Interferon Alpha 2b, Rintatolimod and Celecoxib) in Melanoma Patients With Primary PD-1/PD-L1 Resistance

Clinical trial2025-06-19Terminated · ClinicalTrials.gov

Phase I Clinical Trial Assessing the Combination of Chemokine Modulation With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Clinical trial2023-09-11Results posted · ClinicalTrials.gov

Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma: Phase III Study

Clinical trial2023-04-11Results posted · ClinicalTrials.gov

Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Chemokine Modulation to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Clinical trial2023-03-21Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Interferon alfa-2b

Aliases & brands

IFN alpha-2BInterferon Alfa-2b (E. coli)Intron Ainterferon alfa-2b,recomb.r-INF-alpharIFN-alpha-2bINTERFERON ALFA 2-BInterferon alfa 2bInterferon alpha-2BINTERFERON ALFA-2B,RECOMBINANTInterferon alfa-2b (recombinant)Interferon alfa-2b, recombinantRecombinant Interferon Alfa-2b

RxNorm CUI

5880

ChEMBL ID

CHEMBL1201558

ATC codes

L03AB05

UNII

43K1W2T1M6

Primary mechanism

Interferon alpha/beta receptor agonist